Literature DB >> 7917108

Tumor necrosis factor receptor superfamily members and their ligands.

R J Armitage1.   

Abstract

The tumor necrosis factor (TNF) receptor family comprises a number of type I integral membrane glycoproteins which exhibit sequence homology in their cysteine-rich extracellular domains. Recently, ligands for many of these receptors have been identified. These molecules all display sequence identity with TNF and lymphotoxin beta, prototype ligands for this receptor family, and have the conformation of type II transmembrane molecules. While certain biological activities are common to many members of this TNF-like family, other activities appear to be shared only by some ligands, or are unique. The identification of the TNF superfamily of ligands has provided the opportunity to compare and contrast the diverse biological effects mediated through the interaction of these related molecules with their receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7917108     DOI: 10.1016/0952-7915(94)90119-8

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  43 in total

1.  Deficiency in tumor necrosis factor alpha activity does not impair early protective Th1 responses against blood-stage malaria.

Authors:  H Sam; Z Su; M M Stevenson
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes.

Authors:  Kwang-Mi Kim; Ho Won Kim; Jae-Ouk Kim; Kyoung-Min Baek; Joong Gon Kim; Chang-Yuil Kang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  Functional activity of CD40 antibodies correlates to the position of binding relative to CD154.

Authors:  T A Barr; A W Heath
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

4.  CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity.

Authors:  S Y Lee; S Y Lee; G Kandala; M L Liou; H C Liou; Y Choi
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

5.  Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2.

Authors:  C S Duckett; R W Gedrich; M C Gilfillan; C B Thompson
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

Review 6.  Osteoprotegerin and kidney disease.

Authors:  Alejandra Montañez-Barragán; Isaias Gómez-Barrera; Maria D Sanchez-Niño; Alvaro C Ucero; Liliana González-Espinoza; Alberto Ortiz
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

Review 7.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

Review 8.  TNF superfamily: a growing saga of kidney injury modulators.

Authors:  Maria D Sanchez-Niño; Alberto Benito-Martin; Sara Gonçalves; Ana B Sanz; Alvaro C Ucero; Maria C Izquierdo; Adrian M Ramos; Sergio Berzal; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  Mediators Inflamm       Date:  2010-10-04       Impact factor: 4.711

Review 9.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

10.  Tumor-targeted delivery of biologically active TRAIL protein.

Authors:  H-Y Zhang; J-H Man; B Liang; T Zhou; C-H Wang; T Li; H-Y Li; W-H Li; B-F Jin; P-J Zhang; J Zhao; X Pan; K He; W-L Gong; X-M Zhang; A-L Li
Journal:  Cancer Gene Ther       Date:  2010-01-15       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.